Aurinia Pharmaceuticals (NASDAQ:AUPH) Lowered to “Buy” Rating by StockNews.com

StockNews.com downgraded shares of Aurinia Pharmaceuticals (NASDAQ:AUPH – Free Report) (TSE:AUP) from a strong-buy rating to a buy rating in a report issued on Wednesday. Aurinia Pharmaceuticals Price Performance Shares of NASDAQ AUPH opened at $7.87 on Wednesday. The stock’s 50-day moving average is $8.37 and its two-hundred day moving average is $7.68. The company […]